Sage Journals: Discover world-class research

Abstract

Aims

Estimation of cardiovascular disease risk, using SCORE (Systematic COronary Risk Evaluation) is recommended by European guidelines on cardiovascular disease prevention. Risk estimation is inaccurate in older people. We hypothesized that this may be due to the assumption, inherent in current risk estimation systems, that risk factors function similarly in all age groups. We aimed to derive and validate a risk estimation function, SCORE O.P., solely from data from individuals aged 65 years and older.

Methods and results

20,704 men and 20,121 women, aged 65 and over and without pre-existing coronary disease, from four representative, prospective studies of the general population were included. These were Italian, Belgian and Danish studies (from original SCORE dataset) and the CONOR (Cohort of Norway) study. The variables which remained statistically significant in Cox proportional hazards model and were included in the SCORE O.P. model were: age, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, smoking status and diabetes. SCORE O.P. showed good discrimination; area under receiver operator characteristic curve (AUROC) 0.74 (95% confidence interval: 0.73 to 0.75). Calibration was also reasonable, Hosmer–Lemeshow goodness of fit test: 17.16 (men), 22.70 (women). Compared with the original SCORE function extrapolated to the ≥65 years age group discrimination improved, p = 0.05 (men), p < 0.001 (women). Simple risk charts were constructed. On simulated external validation, performed using 10-fold cross validation, AUROC was 0.74 and predicted/observed ratio was 1.02.

Conclusion

SCORE O.P. provides improved accuracy in risk estimation in older people and may reduce excessive use of medication in this vulnerable population.

Keywords

Risk estimation elderly primary prevention risk factors cardiovascular disease

Get full access to this article

View all access options for this article.

References

United Nations. World population ageing 1950–2050. In: Population division. DESA, Geneva, United Nations, 2002.

World Health Organization website. http:www.who.int (accessed 23 May 2015).

Benetos

Thomas

Bean

. Role of modifiable risk factors in life expectancy in the elderly. J Hypertens 2005; 23: 1803–1808.

Strandberg

Tilvis

. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol 2000; 20: 1057–1060.

Weverling-Rijnsburger

Blauw

Lagaay

. Total cholesterol and risk of mortality in the oldest old. Lancet 1997; 350: 1119–1123.

Anand

Islam

Rosengren

. Risk factors for myocardial infarction in women and men: Insights from the INTERHEART study. Eur Heart J 2008; 29: 932–940.

Beckett

Peters

Fletcher

. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–1898.

Afilalo

Duque

Steele

. Statins for secondary prevention in elderly patients: A hierarchical bayesian meta-analysis. J Am Coll Cardiol 2008; 51: 37–45.

Hermanson

Omenn

Kronmal

. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS registry. N Engl J Med 1988; 319: 1365–1369.

10.

Doll

Peto

Boreham

. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328: 1519–1519.

11.

Mulrow C, Lau J, Cornell J, et al. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev 2000: CD000028.

12.

Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33: 1635–1701.

13.

New Zealand Guidelines Group. The assessment and management of cardiovascular risk. In: New Zealand Primary Care Handbook, New Zealand Ministry for health, 2003.

14.

Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. Healthcare Improvement, Scotland, 2007. Available at: http://www.sign.ac.uk/guidelines/fulltext/97/.

15.

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.

16.

Stork

Feelders

van den Beld

. Prediction of mortality risk in the elderly. Am J Med 2006; 119: 519–525.

17.

de Ruijter

Westendorp

Assendelft

. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: Population based observational cohort study. BMJ 2009; 338: a3083–a3083.

18.

Zethelius

Berglund

Sundstrom

. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107–2116.

19.

Hippisley-Cox

Coupland

Vinogradova

. Predicting cardiovascular risk in England and Wales: Prospective derivation and validation of QRISK2. BMJ 2008; 336: 1475–1482.

20.

D’Agostino

Vasan

Pencina

. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008; 117: 743–753.

21.

Conroy

Pyorala

Fitzgerald

. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003; 24: 987–1003.

22.

Woodward

Brindle

Tunstall-Pedoe

. Adding social deprivation and family history to cardiovascular risk assessment: The ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007; 93: 172–176.

23.

Regional differences in dietary habits, coronary risk factors and mortality rates in Belgium. 1. Design and methodology. Nutrition and health: An interuniversity study. Acta Cardiol 1984; 39: 285–292.

24.

Schroll

Jorgensen

Ingerslev

. The Glostrup population studies, 1964–1992. Dan Med Bull 1992; 39: 204–207.

25.

Presentation of the rifle project risk factors and life expectancy. The RIFLE Research Group. Eur J Epidemiol 1993; 9: 459–476.

26.

Naess

Sogaard

Arnesen

. Cohort profile: Cohort of Norway (CONOR). Int J Epidemiol 2007; 37: 481–485.

27.

Lemeshow

Hosmer

Jr . A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982; 115: 92–106.

28.

Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. In: Proceedings of the fourteenth international joint conference on artificial intelligence 1995, pp.1137–1143. San Francisco, CA, USA: Morgan Kaufmann Publishers Inc.

29.

Steyerberg

Vergouwe

. Towards better clinical prediction models: Seven steps for development and an ABCD for validation. Eur Heart J 2014; 35: 1925–1931.

30.

Paunio

Heinonen

Virtamo

. HDL cholesterol and mortality in Finnish men with special reference to alcohol intake. Circulation 1994; 90: 2909–2918.

31.

De Backer

Graham

Cooney

. Do novel biomarkers add to existing scores of total cardiovascular risk? Eur J Prev Cardiol 2012; 19: 14–17.

32.

Lewington

Clarke

Qizilbash

. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.

33.

Lewington

Whitlock

Clarke

. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829–1839.

34.

Cooney MT, Dudina A, De Bacquer D, et al. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Eur J Cardiovasc Prev Rehabil 2009; 16: 304–314.

35.

Graham

Atar

Borch-Johnsen

. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14(Suppl. 2): S1–S113.

36.

Jackson

. Which elderly patients should be considered for anti-hypertensive treatment? An evidence-based approach. J Hum Hypertens 1998; 12: 607–613.

37.

Christiaens

. Cardiovascular risk tables. BMJ 2008; 336: 1445–1446.

38.

D’Agostino

Sr Vasan

Pencina

. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008; 117: 743–753.

39.

Sakshaug S, Strøm H, Lie Berg C et al. Drug consumption in Norway 2005–2009. Oslo: Norwegian Institute of Public Health, 2010.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.20 MB

Cardiovascular risk estimation in older persons: SCORE O.P.